Arno Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016 . For the three months ended June 30, 2016, the reported net loss of $2.1 million, or $0.05 per share, which includes non-cash income of $1.1 million related to the decrease in derivative liability of common stock warrants, and $1.0 million of non-cash stock based compensation expense. Adjusting for these non-cash items, which resulted in an income of $0.1 million, the Company reported a net loss of approximately $2.2 million, or $0.05 per share, on a non-GAAP basis. Adjusted second quarter 2015 net loss was approximately $3.0 million, or $0.15 per share, on a non-GAAP basis, which includes the same non-cash adjustments as second quarter 2016. On a GAAP basis, second quarter 2015 net loss was $3.4 million, or $0.17 per share. The primary factors for the $0.8 million year-over-year improvement in adjusted (non-GAAP) net loss in the second quarter of 2016 compared to the second quarter of 2015 were reduced spending of $0.2 million on onapristone’s pre-clinical and non-clinical research activities mostly offset by costs associated with terminating onapristone’s Phase I/II clinical trial evaluating onapristone in women with progesterone receptor (PR) expressing tumors and lower compensation expense of $0.5 million. Loss from operations was $3.310 million against $3.979 million a year ago. For the six months ended June 30, 2016, the company reported net loss of $5.9 million, or $0.15 per share, which includes non-cash income of $0.2 million related to the decrease in derivative liability of common stock warrants, and $1.9 million of non-cash stock based compensation expense. Adjusting for these non-cash items, which resulted in an expense of $1.7 million, the Company reported a net loss of approximately $4.2 million, or $0.10 per share, on a non-GAAP basis. This compares to an adjusted non-GAAP net loss for the first half of 2015 of approximately $5.9 million, or $0.29 per share, when considering the same non-cash adjustments as for the first half 2016. On a GAAP basis, first half 2015 net loss was $6.8 million, or $0.33 per share. The primary factors for the $1.7 million year-over-year improvement in adjusted (non-GAAP) net loss in the first half of 2016 compared to the first half of 2016 were reduced spending of $0.8 million on onapristone’s pre-clinical and non-clinical research activities mostly offset by costs associated with terminating onapristone’s Phase I/II clinical trial evaluating onapristone in women with progesterone receptor (PR) expressing tumors and lower compensation expense of $0.7 million. Loss from operations was $6.135 million against $7.842 million a year ago.